SEARCH

SEARCH BY CITATION

References

  • 1
    Strasser SI, McDonald GB. Hepatobiliary complications of hematopoietic stem cell transplantation. In: SchiffER, SorrellMF, MaddreyWC, eds. Schiff's Diseases of the Liver. 9th ed. Philadelphia: J. B. Lippincott Co., 2003: 16361663.
  • 2
    Deleve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venocclusive disease). Semin Liver Dis 2002; 22: 2741.
  • 3
    Strasser SI, Shulman HM, McDonald GB. Cholestasis after hematopoietic cell transplantation. Clin Liver Dis 1999; 3: 651668.
  • 4
    Fingeroth JD. Herpesvirus infection of the liver. Infect Dis Clin North Am 2000; 14: 689719.
  • 5
    Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, et al. Hepatitis C virus infection after bone marrow transplantation: a cohort study with 10 year follow-up. HEPATOLOGY 1999; 29: 18931899.
  • 6
    Strasser SI, Shulman HM, Flowers ME, Reddy R, Margolis DA, Prumbaum M, et al. Chronic graft-vs-host disease of the liver: presentation as an acute hepatitis. HEPATOLOGY 2000; 32: 12651271.
  • 7
    Malik AH, Collins JRH, Saboorian MH, Lee WM. Chronic graft versus host disease (GVHD) following hematopoietic cell transplantation (HCT) presenting as an acute hepatitis. Am J Gastroenterol 2001; 96: 588590.
    Direct Link:
  • 8
    Akpek G, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood 2002; 100: 39033907.
  • 9
    Lau GKK, Strasser SI, McDonald GB. Hepatitis virus infections in patients with cancer. In: WingardJR, BowdenRA, eds. Management of Infection in Oncology Patients. London: Martin Dunitz, 2003: 321342.
  • 10
    Strasser SI, Kowdley KV, Sale GE, McDonald GB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 1998; 22: 167173.
  • 11
    Murakami CS, Louie W, Chan GS, O'Donnell M, David D, Forman SJ, et al. Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes. Bone Marrow Transplant 1999; 23: 921927.
  • 12
    Rossetti F, Brawner DL, Bowden RA, Meyer WG, Schoch HG, Fisher L, et al. Fungal liver infection in marrow transplant patients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995; 20: 801811.
  • 13
    van Burik JH, Leisenring W, Myerson D, Hackman RC, Shulman HM, Sale GE, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246254.
  • 14
    Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 40634071.
  • 15
    Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton: Chapman and Hall/CRC, 2003.
  • 16
    Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 17291736.
  • 17
    Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 14641472.
  • 18
    Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 1996; 125: 625633.
  • 19
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001; 33: 464470.
  • 20
    Krzeski P, Zych W, Kraszewska E, Milewski B, Butruk E, Habior A. Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? HEPATOLOGY 1999; 30: 865869.
  • 21
    Zager RA. Acute renal failure in the setting of bone marrow transplantation. Kidney Int 1994; 46: 14431458.
  • 22
    Kostopanagiotou G, Routsi C, Smyrniotis V, Lekka ME, Kitsiouli E, Arkadopoulos N, et al. Alterations in bronchoalevolar lavage fluid during ischemia-induced acute hepatic failure in the pig. HEPATOLOGY 2003; 37: 11301138.
  • 23
    Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. HEPATOLOGY 2000; 32: 734739.
  • 24
    Krowka MJ, Cortese DA. Pulmonary aspects of liver disease and liver transplantation. Clin Chest Med 1989; 10: 593616.
  • 25
    Baudouin SV, Howdle P, O'Grady JG, Webster NR. Acute lung injury in fulminant hepatic failure following paracetamol poisoning. Thorax 1995; 50: 399402.
  • 26
    Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002; 35: 478491.
  • 27
    Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. HEPATOLOGY 2003; 38: 15081515.
  • 28
    Tsai MH, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003; 125: 14521461.
  • 29
    Matuschak G. Liver-lung interaction in critical illness. In: PinskyMR, DrainautJF, ArtigasA, eds. The Splanchnic Circulation: No Longer a Silent Partner. Update in Intensive Care and Emergency Medicine. Vol. 23. New York: Berlin Heidelberg, 1995: 7393.
  • 30
    Fink J, Cooper M, Burkhart K, McDonald GB, Zager RA. Marked enzymuria following bone marrow transplantation: a correlate of veno-occlusive disease-induced “hepatorenal syndrome”. J Am Soc Nephrol 1995; 6: 16551660.
  • 31
    McDonald GB, Hinds MS, Fisher LB, Schoch HG, Wolford JL, Banaji M, et al. Venocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255267.
  • 32
    Gruss E, Bernis C, Tomas JF, Garcia-Canton C, Figuera A, Motellon JL, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995; 15: 473479.
  • 33
    Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia—the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 30553060.
  • 34
    Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477485.
  • 35
    McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 20432048.
  • 36
    Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820826.
  • 37
    Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch G, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 7682.
  • 38
    Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975981.
  • 39
    Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. The Nordic Bone Marrow Transplantation Group. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 19771983.
  • 40
    Ruutu T, Remberger M, Remes K, Juvonen E, Volin L, Eriksson B, et al. Improved survival with ursodeoxycholic acid (UDCA) prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study of the Nordic Bone Marrow Transplantation Group. Blood 2002; 100: 111a.
  • 41
    Richardson PG, Murakami C, Jin Z, Warren DL, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplant with severe veno-occlusive disease and multi-system organ failure: response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100: 43374343.
  • 42
    Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 11221129.
  • 43
    Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, et al. Transjugular liver biopsy in bone marrow transplantation. Bone Marrow Transplant 1993; 11: 2126.
  • 44
    Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 10151022.
  • 45
    Snover DC, Weisdorf SA, Ramsay AK, McGlave P, Kersey JH. Hepatic graft-versus-host disease: a study of the predictive value of liver biopsy in diagnosis. HEPATOLOGY 1984; 4: 123130.
  • 46
    Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human marrow transplantation. HEPATOLOGY 1988; 8: 463470.
  • 47
    Stockschlaeder M, Storb R, Pepe M, Longton G, McDonald GB, Anasetti C, et al. A pilot study of low dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. Br J Haematol 1992; 80: 4954.
  • 48
    List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia J Clin Oncol 1993; 11: 16521660.